OTLK - Outlook Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Outlook Therapeutics, Inc.

7 Clarke Drive
Cranbury, NJ 08512
United States
609-619-3990
http://www.outlooktherapeutics.com

Sector
Industry
Full Time Employees56

Key Executives

NameTitlePayExercisedYear Born
Mr. Lawrence A. KenyonPres, CEO, CFO, Company Sec., Treasurer & Director389.94kN/A1966
Mr. Terry DagnonChief Operating OfficerN/AN/A1962
Rick GregoryDirector of Marketing & CommunicationsN/AN/AN/A
Mr. Jeffrey EvansonChief Commercial OfficerN/AN/A1969
Dr. Balu N. Balasubramanian Ph.D.AdvisorN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Corporate Governance

Outlook Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.